Effects of short-term treatment with befuraline on sleep and REM-inducing activity of physostigmine

L. Ferini-Strambi, F. Minicucci, M. Franceschi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Befuraline is a new antidepressant compound active in some animal models of depression and in human affective disorders. It is a direct adrenergic agonist and an inhibitor of norepinephrine and serotonin uptake and cyclic adenosine monophosphate phosphodiesterase activity. It has no central anticholinergic properties. Its effects on nocturnal sleep and rapid-eye-movement (REM)-inducing action of physostigmine were investigated in eight young male volunteers after one week of treatment with 50 mg BID. The results of the study show that befuraline increases REM latency without significantly modifying other REM and non-REM sleep parameters. These findings indicate that befuraline, as the other antidepressant drugs, has REM suppressant activity, perhaps only partially revealed by our study because of its short term and low dosage and because it was performed in healthy subjects. However, befuraline successfully counteracts the REM-inducing action of physostigmine since the latter cannot further decrease REM latency after one week of treatment. Both these results confirm the experimental data on the lack of central anticholinergic properties of befuraline and indicate that at least some biochemical mechanisms of the drug are already active after one week of treatment.

Original languageEnglish
Pages (from-to)48-56
Number of pages9
JournalCurrent Therapeutic Research
Volume41
Issue number1
Publication statusPublished - 1987

Fingerprint

Physostigmine
REM Sleep
Sleep
Cholinergic Antagonists
Antidepressive Agents
Therapeutics
Adrenergic Agonists
Phosphoric Diester Hydrolases
Eye Movements
Mood Disorders
Cyclic AMP
befuraline
Volunteers
Healthy Volunteers
Animal Models
Depression
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of short-term treatment with befuraline on sleep and REM-inducing activity of physostigmine. / Ferini-Strambi, L.; Minicucci, F.; Franceschi, M.

In: Current Therapeutic Research, Vol. 41, No. 1, 1987, p. 48-56.

Research output: Contribution to journalArticle

@article{6c58ad0d967043edbc3e5f1a236c880d,
title = "Effects of short-term treatment with befuraline on sleep and REM-inducing activity of physostigmine",
abstract = "Befuraline is a new antidepressant compound active in some animal models of depression and in human affective disorders. It is a direct adrenergic agonist and an inhibitor of norepinephrine and serotonin uptake and cyclic adenosine monophosphate phosphodiesterase activity. It has no central anticholinergic properties. Its effects on nocturnal sleep and rapid-eye-movement (REM)-inducing action of physostigmine were investigated in eight young male volunteers after one week of treatment with 50 mg BID. The results of the study show that befuraline increases REM latency without significantly modifying other REM and non-REM sleep parameters. These findings indicate that befuraline, as the other antidepressant drugs, has REM suppressant activity, perhaps only partially revealed by our study because of its short term and low dosage and because it was performed in healthy subjects. However, befuraline successfully counteracts the REM-inducing action of physostigmine since the latter cannot further decrease REM latency after one week of treatment. Both these results confirm the experimental data on the lack of central anticholinergic properties of befuraline and indicate that at least some biochemical mechanisms of the drug are already active after one week of treatment.",
author = "L. Ferini-Strambi and F. Minicucci and M. Franceschi",
year = "1987",
language = "English",
volume = "41",
pages = "48--56",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Effects of short-term treatment with befuraline on sleep and REM-inducing activity of physostigmine

AU - Ferini-Strambi, L.

AU - Minicucci, F.

AU - Franceschi, M.

PY - 1987

Y1 - 1987

N2 - Befuraline is a new antidepressant compound active in some animal models of depression and in human affective disorders. It is a direct adrenergic agonist and an inhibitor of norepinephrine and serotonin uptake and cyclic adenosine monophosphate phosphodiesterase activity. It has no central anticholinergic properties. Its effects on nocturnal sleep and rapid-eye-movement (REM)-inducing action of physostigmine were investigated in eight young male volunteers after one week of treatment with 50 mg BID. The results of the study show that befuraline increases REM latency without significantly modifying other REM and non-REM sleep parameters. These findings indicate that befuraline, as the other antidepressant drugs, has REM suppressant activity, perhaps only partially revealed by our study because of its short term and low dosage and because it was performed in healthy subjects. However, befuraline successfully counteracts the REM-inducing action of physostigmine since the latter cannot further decrease REM latency after one week of treatment. Both these results confirm the experimental data on the lack of central anticholinergic properties of befuraline and indicate that at least some biochemical mechanisms of the drug are already active after one week of treatment.

AB - Befuraline is a new antidepressant compound active in some animal models of depression and in human affective disorders. It is a direct adrenergic agonist and an inhibitor of norepinephrine and serotonin uptake and cyclic adenosine monophosphate phosphodiesterase activity. It has no central anticholinergic properties. Its effects on nocturnal sleep and rapid-eye-movement (REM)-inducing action of physostigmine were investigated in eight young male volunteers after one week of treatment with 50 mg BID. The results of the study show that befuraline increases REM latency without significantly modifying other REM and non-REM sleep parameters. These findings indicate that befuraline, as the other antidepressant drugs, has REM suppressant activity, perhaps only partially revealed by our study because of its short term and low dosage and because it was performed in healthy subjects. However, befuraline successfully counteracts the REM-inducing action of physostigmine since the latter cannot further decrease REM latency after one week of treatment. Both these results confirm the experimental data on the lack of central anticholinergic properties of befuraline and indicate that at least some biochemical mechanisms of the drug are already active after one week of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0023117521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023117521&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 48

EP - 56

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 1

ER -